Search

Twist Bioscience Corp

Закрыт

СекторЗдравоохранение

32.03 3.12

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

30.39

Макс.

33.31

Ключевые показатели

By Trading Economics

Доход

-48M

-27M

Продажи

3M

99M

Прибыль на акцию

-0.45

Рентабельность продаж

-27.41

Сотрудники

979

EBITDA

3.2M

-21M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+23.67% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

31M

1.9B

Предыдущая цена открытия

28.91

Предыдущая цена закрытия

32.03

Новостные настроения

By Acuity

50%

50%

159 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

17 дек. 2025 г., 23:50 UTC

Популярные акции

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

17 дек. 2025 г., 23:20 UTC

Отчет

Correction to Micron Logs Sales Jump Article

17 дек. 2025 г., 23:07 UTC

Отчет

Micron Logs Sales Jump, Sees Further Growth as AI Demand Outpaces Supply -- Update

17 дек. 2025 г., 21:37 UTC

Отчет

Micron Technology 1Q Sales Jump 57%, Led By Memory Growth

17 дек. 2025 г., 23:53 UTC

Обсуждения рынка

Gold Edges Higher, Supported by Some Tailwinds -- Market Talk

17 дек. 2025 г., 23:43 UTC

Обсуждения рынка

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

17 дек. 2025 г., 23:06 UTC

Приобретения, слияния, поглощения

Asahi Group: Transaction Expected to Be Closed in 2H of Calendar Year 2026

17 дек. 2025 г., 23:05 UTC

Приобретения, слияния, поглощения

Asahi Group: Currently No Plans of Issuing New Shares in Asahi

17 дек. 2025 г., 23:04 UTC

Приобретения, слияния, поглощения

Asahi Group: Funds to Be Provided Via Borrowings From Financial Institutions or Cash on Hand

17 дек. 2025 г., 23:03 UTC

Приобретения, слияния, поглощения

Asahi Group: Acquisition of 53.68% Stake in UDV (Kenya) is $646M on Equity Value Basis

17 дек. 2025 г., 23:02 UTC

Приобретения, слияния, поглощения

Asahi Group: Acquisition of 100% Stake in Diageo Kenya is $2.354B on Equity Value Basis

17 дек. 2025 г., 22:59 UTC

Приобретения, слияния, поглощения

Asahi Group: Deal Part of Strategy Under Medium- to Long-Term Management Policy

17 дек. 2025 г., 22:57 UTC

Приобретения, слияния, поглощения

Asahi Group: To Indirectly Acquire 65.00% Stake in East African Breweries PLC

17 дек. 2025 г., 22:56 UTC

Приобретения, слияния, поглощения

Asahi Group: Stakes Acquired From Two Subsidiaries of Diageo Plc

17 дек. 2025 г., 22:55 UTC

Приобретения, слияния, поглощения

Asahi Group Holdings: To Acquire 100% Stake in Diageo Kenya Ltd., 53.68% Stake in UVD (Kenya) Ltd.

17 дек. 2025 г., 22:49 UTC

Обсуждения рынка

Sandfire Resources Production Pipeline Strength Questioned -- Market Talk

17 дек. 2025 г., 21:58 UTC

Отчет

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17 дек. 2025 г., 21:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Tech, Media & Telecom Roundup: Market Talk

17 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

17 дек. 2025 г., 21:46 UTC

Отчет

Salesforce and Other AI Stocks That Can Catch Up to the Pack -- Barrons.com

17 дек. 2025 г., 21:20 UTC

Отчет

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17 дек. 2025 г., 21:10 UTC

Отчет

Micron Beats Earnings. The Stock Is Rising. -- Barrons.com

17 дек. 2025 г., 21:05 UTC

Отчет

Micron Technology Anticipates Business Performance to Continue Strengthening Through FY26

17 дек. 2025 г., 21:04 UTC

Отчет

Micron Technology: 2Q Outlook Reflects Substantial Records Across Rev, Gross Margin, EPS and Free Cash Flow >MU

17 дек. 2025 г., 21:04 UTC

Отчет

Micron Technology Sees 2Q Oper Expenses $1.56B, Plus or Minus $20M >MU

17 дек. 2025 г., 21:03 UTC

Отчет

Micron Technology Sees 2Q Adj EPS $8.42, Plus or Minus 20c >MU

17 дек. 2025 г., 21:03 UTC

Отчет

Micron Technology Sees 2Q EPS $8.19, Plus or Minus 20c >MU

17 дек. 2025 г., 21:03 UTC

Отчет

Micron Technology Sees 2Q Revenue $18.7B, Plus or Minus $400M >MU

17 дек. 2025 г., 21:02 UTC

Отчет

Micron Technology 1Q Operating Cash Flow $8.41 B >MU

17 дек. 2025 г., 21:01 UTC

Отчет

Micron Technology 1Q Rev $13.64B >MU

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

23.67% рост

Прогноз на 12 месяцев

Средняя 38.5 USD  23.67%

Максимум 42 USD

Минимум 32 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

5

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

159 / 374Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat